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Gregory L. Moneta, MD, Abstracts Section EditorSurgical management of groin lymphatic complications after arterial
bypass surgery
Shermak MA, Yee K, Wong L. Plast Reconstr Surg 2005;115:1954-62.
Conclusion: Muscle flaps are effective therapy for groin lymphatic
complications after arterial surgery.
Summary: Using operating room records and patient databases, the
authors retrospectively reviewed groin lymphatic complications. Manage-
ment of these complications included percutaneous methods, excision,
and/or muscle flap coverage, and ligation of leaking lymphatics. From June
1999 to June 2002, 538 patients were identified with arterial revasculariza-
tion procedures involving the groin; 34 lymphatic groin complications
occurred in 27 patients (7 patients with bilateral complications). In 85% of
cases of groin lymphatic complications, a prosthetic graft was present in the
groin. Ten patients had had a previous operation in the same groin. Groin
lymphatic complications were identified at a mean of 14 days after surgery.
Presentations included swelling (n 16), drainage (n 13), erythema (n
4), and leg edema (n  1).
Twelve of the 34 complication sites were managed with excision,
drainage, or both, and 22weremanaged withmuscle flap surgery. Ten of the
complication sites managed with muscle flap surgery had failed less aggres-
sive therapy. The most common muscle flap used in this study was the
gracilis flap in 19, with one each sartorius, rectus abdominis, and rectus
femoral flap also used. Interoperative cultures were positive from 23 of the
34 complication sites. Four of the patients with muscle flap coverage of the
groin lymphatic leak had complicated postoperative recoveries. In all cases
associated with muscle flap coverage of lymphatic leaks, the lymphatic leak
was controlled.
Comment: The results indicate patients with persistent lymphatic leaks
after arterial surgery can be successfully treated with muscle flap coverage of
the wound. The success rate appears sufficiently high. One should consider
bypassing the preliminary traditional treatment of reoperation and reclosure
over a drain and insteadmove straight to definitive therapy with amuscle flap
to control the groin lymphatic leak.
Sirolimus-eluting and paclitaxel-eluting stents for coronary
revascularization
Windecker S, RemondinoA, Eberli FR, et al.NEngl JMed, 2005;353:653-62.
Conclusion: Sirolimus-eluting stents provide slightly superior clinical
and angiographic outcomes than paclitaxel-eluting stents in the coronary
circulation.
Summary: This was a randomized, single, blind, controlled trial com-
paring sirolimus-eluting stents with paclitaxel-eluting stents in patients
undergoing coronary artery stent procedures. There were 1,012 patients
entered into the study, and the primary end-point was a composite of major
adverse cardiac events, including myocardial infarction, death from cardiac
cause, and ischemia-driven revascularization of the target lesion at 9months.
Follow-up angiograms were available in 540 (53.4%) of the 1,012 patients.
The two groups of stent patients had similar clinical and angiographic
characteristics at entry into the study.
At 9 months, the major adverse cardiac rate was 6.2% in the sirolimus-
eluting stent group and 10.8% in the paclitaxel stent group (hazard ratio
[HR], 0.56; 95% confidence interval [CI], 0.36 to 0.86; P  .009). Target
vessel revascularization drove the difference between the sirolimus-eluting
and paclitaxel-eluting stents. Target vessel revascularization by 9months was
4.8% in the sirolimus-eluting stent group vs 8.3% in the paclitaxel-eluting
stent group (HR, 0.56; 95% CI, 0.34 to 0.93; P  .003). There were no
significant differences in rates of death from cardiac causes or occurrence of
myocardial infarction in the patients in either stent group. Angiographic
restenosis was present in 6.6% of patients with sirolimus-eluting stents and
11.5% of patients with paclitaxel-eluting stents.
Comment: This report, along with currently available data from ran-
domized clinical trials and registries (see Table I of the article), suggests a
clinical and angiographic advantage of sirolimus-eluting stents over paclitax-
el-eluting stents for coronary revascularization. This whole field will likely
need to be re-examined as the technology evolves. Currently, trials are
already underway involving second-generation drug-eluting stents with
different stent platforms, stent struts, drugs, and polymers.
Leisure time, occupational, and commuting physical activity and the
risk of stroke
Hu G, Sarti C, Jousilahti P. Stroke 2005;36:1994-9.Conclusion: High levels of leisure time activity reduce risk of stroke
secondary to subarachnoid hemorrhage, intracerebral hemorrhage, andischemic stroke. Ischemic stroke can also be reduced by daily commuting
activity.
Summary: Exercise is thought to reduce the risk of cardiovascular
disease; however, the role of physical activity, especially commuting physical
activity and occupational activity with respect to stroke risk reduction, is not
well established. The authors examined the relationship between leisure
time, occupational-associated, and commuting physical activity, with both
type-specific and total risk of stroke.
There were 47,721 subjects aged 25 to 64 years (23,841 men and
24,880 women) in the study. Patients were derived from six independent
population surveys in five different geographic areas of Finland. Patients did
not have a history of coronary heart disease, stroke, or cancer at baseline. The
authors calculated hazard ratios for the incident of stroke with estimated
different levels of occupational, leisure, and commuting physical activity.
Each form of physical activity was divided into three categories, low,
moderate, or high, varying from almost no activity (low) to intense physical
activity (high).
A multivariant adjusted analysis with adjustments for age, sex, area,
study year, body mass index, systolic blood pressure, serum cholesterol
levels, education, smoking, alcohol consumption, diabetes, and other two
types of physical activity, indicated hazard ratios associated with low, mod-
erate, and high leisure time physical activity for total stroke were 1.00, 0.86,
and 0.74 (P trend .001). For subarachnoid hemorrhage, hazard ratios for
low, moderate, and high leisure time activity were 1.00, 0.87, and 0.46 (P
trend  .011). For intra-cerebral hemorrhage, hazard ratios for low, mod-
erate, and high leisure time physical activity were 1.00, 0.77, and 0.63 (P
trend .024). Similar hazard ratios for ischemic stroke were 1.00, 0.87, and
0.80 (P trend  .001). For total stroke, multivariant adjusted hazard ratios
associated with none, 1 to 29, and 30 minutes of active commuting were
1.00, 0.92, and 0.89 (P trend  .043). For ischemic stroke, hazard ratios
were 1.00, 0.93, and 0.86 (P trend  .028). Simultaneous engagement in
two or three types of physical activity showed slightly stronger protected
effects than one activity alone.
Comment:Of all studies investigating the effects of physical activity on
stroke, this study has the largest sample size and the largest proportion of
women. The results must be taken seriously. The study is limited, however,
by the use of self-reported assessment of physical activity. There are also no
data on possible changes in physical activity during follow-up. It is likely
patients over-report their physical activity. This would, however, tend to
lead to an underestimation of the association between physical activity and
stroke risk reduction and does not detract from the conclusion that physical
activity reduces stroke risk.
Fatal pulmonary embolism in hospitalized patients: A necropsy review
Alikhan R, Peters F, Wilmott R, et al. J Clin Path 2004; 57:1254-7.
Conclusion: Among hospitalized patients, fatal pulmonary embolism
(PE) occurs more frequently in patients hospitalized for medical than for
surgical conditions.
Summary: The authors retrospectively reviewed postmortem reports
from 1991 to 2000 at Kings College Hospital in London. They assessed the
number of deaths secondary to PE determined by autopsy among hospital-
ized patients.
Over the 10 years 16,104 in-hospital deaths occurred, and 6,833
(42.4%) autopsies were performed. The cause of death as determined by
autopsy was PE in 3.9% of cases. PEwas the cause of death in 5.2% of all adult
deaths confirmed by autopsy. No deaths from PE occurred in patients 18
years of age, and 80% of the deaths occurred in patients60 years of age. Of
the autopsy-confirmed deaths by PE, 214 (80.8%) occurred in patients who
had not undergone a recent operation. Of the patients who had not
undergone recent surgery, 110 (51.4%) had had an acute medical illness
sometime in the 6 weeks before their death from PE.
Comment: This is a follow-up of a previous study from Kings College
that examined the period from 1965 to 1990. At that time, they had
determined that deaths from PE in surgical patients appeared to be decreas-
ing. The current report validates the previous report and documents a
continuing decrease in the proportion of overall PE deaths in patients who
had been surgical patients. Advances in surgical care and thromboprophy-
laxis appear to have had some effect. A greater emphasis on thrombopro-
phylaxis is needed in patients hospitalized for medical conditions.
Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide
targeted at   integrin after murine hindlimb ischemiaV 3
Hua J, Dobrucki LW, Sadeghi M, et al. Circulation 2005;111:3255-60
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tracer that selectively localizes to endothelial cells in regions of increased
angiogenesis can be used to noninvasively assess areas of active angiogenesis.
Summary: The efficacy of angiogenesis therapies is being increasingly
assessed with noninvasive imaging strategies. Because V3 integrin is
activated in angiogenic vessels, it therefore represents a potential target for
noninvasive imaging of angiogenesis. The authors used a 99m Tc-labeled
peptide (NC100692) targeted for V3 integrin with an established murine
model of angiogenesis induced by hind-limb ischemia. Nine control mice
and 29 mice with surgical femoral artery occlusion were injected with
NC1000692 at 1, 3, 7, and 14 days after femoral occlusion. The tracer was
imaged with in vivo pinhole planar gamma camera imaging. Gamma well
counting and immunostaining were also performed in tissues harvested from
the hind limb both proximal and distal to the femoral artery occlusion.
In vivo pinhole images revealed increased focal NC1000692 activity
distal to the femoral artery occlusion at days 3 and 7. This was confirmed
with gamma well counting. Angiogenesis in the ischemic hind limb was also
confirmed at the same time points by lectin staining. Endothelial cell
specificity was confirmed in tissue sections using a fluorescent analog tar-
geted at the V3 integrin and dual immunofluorescent staining of the
endothelium.
Comment: This may be a major advance in the field of angiogenesis.
The approach offers the ability to serially evaluate the angiogenic process in
experimental animals without the need for euthanization at distinct time
points. In addition, it targets the angiogenic process itself rather than more
standard measures of the physiologic consequences of angiogenesis such as
an increase in tissue oxygenation. The favorable clearance kinetics of
NC100692 may potentially allow noninvasive assessment of angiogenesis in
patients undergoing various drug therapies for peripheral vascular disease.
Carotid artery stents for blunt cerebral vascular injury: risks exceed
benefits
Cothren CC, Moore EE, Ray CE Jr, et al. Arch Surg 2005;140:480-6.
Conclusion: Patients who have carotid artery stents placed for pseu-
doaneurysm after blunt cerebral vascular injury have unacceptable peripro-
cedural complication rates and late occlusion rates of the treated internal
carotid artery.
Summary: A grade III carotid artery injury after blunt trauma is a
pseudoaneurysm of the carotid artery. It has been suggested that arteries
with grade III injuries be treated with carotid stents because of possible
persistence of pseudoaneurysm and subsequent embolization or rupture.
The current study was an analysis of a prospective database of all patients
with blunt carotid artery injuries at a level I urban trauma center. A
comprehensive screening programwith angiography was initiated in patients
with appropriate patterns of injury to assess for blunt carotid artery injuries.
Documented injuries to the carotid artery in patients without contraindica-
tions to anticoagulation were treated with anticoagulation immediately.
Patients with persistent pseudoaneurysm documented on a follow-up arte-
riogram 7 to 10 days later were candidates for stent placement.
From January 1, 1996, to May 1, 2004, 46 patients were discovered by
angiography to have sustained blunt carotid pseudoaneurysm, and 23 of the
patients underwent carotid artery stent placement. With stent placement,
three strokes and one subclavian dissection occurred. Follow-up arteriogra-
phy was performed in 38 patients; 20 patients received antithrombotic
agents alone, and 18 patients with stents received stents and antithrombotic
agents. Despite use of concurrent anticoagulation therapy, poststent carotid
occlusion developed in eight patients with carotid artery stents. This 45%
incidence of poststent carotid artery occlusion in the patients with stents was
significantly different from the 5% incidence in those who were treated with
antithrombotic agents alone. In patients not treated with stents, the only
complication was a middle cerebral artery stroke in a patient not treated with
antithrombotic therapy.
Comment: The study indicates the relative safety and efficacy of
anticoagulation therapy for patients with pseudoaneurysm after blunt ca-
rotid artery injury. The carotid occlusion rate in patients treated with stents
is alarming. The antithrombotic regimen used in the patients treated with
stents was heparin. Perhaps better results could have been obtained with the
use of clopidogrel or perhaps even a combination of clopidogrel and heparin.
Further investigations using alternative antithrombotic agents in patients
with carotid stents for blunt carotid artery trauma are warranted. The data
indicate antithrombotic therapy alone is effective for most patients with
pseudoaneurysm after carotid artery injury. If stenting must be done for
pseudoaneurysm after carotid artery injury, an alternative form of peripro-
cedural antithrombotic therapy other than just heparin should be used.
Clearly, the results of the combination of heparin and stents are suboptimal.Cost-effectiveness of endovascular abdominal aortic aneurysm repair
Michaels JA, Drury D, Thomas SM. Br J Surg 2005;92:960-7.
Conclusion: For fit patients, endovascular aneurysm repair (EVAR) is
unlikely to be within the accepted range of cost-effectiveness for new
technology. For patients unfit for open repair, who have an expected
operative mortality of 40%, EVAR may be the treatment of choice.
Summary: The authors used economic modeling and sensitivity anal-
ysis to consider reference cases representing a 70 year-old-man with 5.5-cm
abdominal aortic aneurysm (AAA) who was fit for surgery (RC1) and an
80-year-old man with a 6.5-cm AAA considered unfit for open surgery
(RC2). They assessed incremental cost-effectiveness ratios to compare open
repair in RC1 vs conservative management in RC2.
In RC1, EVAR resulted in a gain of 0.1 quality-adjusted life-years
(QUALYs). This was an estimated cost of £11,449, with an incremental cost
effectiveness ratio of £110,000 per QUALY. In RC1, over a range of
sensitivity analyses and alternative scenarios, EVAR consistently had incre-
mental cost-effectiveness ratios £30,000 per QUALY. This would not
normally be considered within the range or level appropriate for funding by
the British National Health Service.
In the RC2 case, EVAR resulted in an estimated benefit of 1.64
QUALYs. The incremental cost was £14,077, with an incremental cost per
QALY of £8,579, making EVAR potentially cost-effective in patients un-
suitable for open repair when the expected mortality of the open procedure
was 40%.
Comment: The data suggest that in patients suitable for both EVAR
and open repair, EVAR is not cost-effective but that it may be cost- effective
in patients unsuitable for open repair, but only if they have what is basically
a prohibitive projected operative mortality.
Economic modeling is a means of trying to help guide the introduction
of new technology into the health-care system. It is obviously a surrogate—
and a relatively poor surrogate—for well-conducted randomized trials. This
type of data will be of some interest to health-care policy makers. However,
the field of endovascular aneurysm repair is evolving so rapidly that I doubt
either patients or physicians will permit what is essentially speculation to
drive the availability of EVAR.
Endovascular brachytherapy: Restenosis in de novo versus recurrent
lesions of femoral-popliteal artery—the Vienna experience
Wolfram RM, Budinsky AC, Prokrajac B. Radiology 2005, 236:338-42.
Conclusion: Endovascularly administered brachytherapy with gamma
radiation may reduce the rate of restenosis after femoral-popliteal angio-
plasty for recurrent but not de novo lesions.
Summary: Interest continues in the ability of brachytherapy to reduce
restenosis after angioplasty. In the current study, the authors sought to
determine restenosis rates after brachytherapy, compared with controls, in
patients undergoing femoral-popliteal angioplasty for de novo lesions vs
patients undergoing femoral-popliteal angioplasty for recurrent stenosis.
Percutaneous transluminal angioplasty (PTA) was used to treat 199 patients
(mean age, 71.9  6 years; 115 men, 84 women), 100 of which were also
treated with brachytherapy and 99 were treated with PTA alone. Of the 134
patients with a de novo lesion, 66 were assigned to the combination of PTA
and brachytherapy. Of the 65 patients with recurrent lesions, 34 were
assigned to the combination of PTA and brachytherapy. The remaining
patients in each group were treated with PTA alone. Kaplan-Meier curves
were calculated and the log-rank test used to determine freedom from
recurrence in both groups at 12 months.
At 12 months, in patients with de novo lesions, there was no significant
difference in recurrence rates between 24 (35%) of 66 patients who under-
went brachytherapy and PTA vs 30 (44%) of 66 who underwent PTA alone
(P  .32). In patients undergoing PTA for recurrent lesions, there was a
significant difference in the rate of restenosis for recurrent lesions in 9 (26%)
of 34 patients who received brachytherapy vs 22 (71%) of 34 who did not (P
 .004).
Comment:The study suggests that different strategies may be required
to reduce restenosis after PTA of de novo vs recurrent stenotic lesions.
Brachytherapy continues to be evaluated as a means of reducing restenosis
after percutaneous transluminal angioplasty. Given the relatively cumber-
some techniques involved and the logistic difficulties in administering
gamma radiation, investigations in this field have been somewhat limited.
Nevertheless, some patient and lesion combinations may appear to benefit
from brachytherapy. Continued investigation is warranted. Larger, multi-
center trials will be required to prove the utility of this technique as an
adjunct to catheter based therapies for arterial stenosis.
